These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33008453)

  • 1. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
    Lancman G; Mascarenhas J; Bar-Natan M
    J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 10. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
    Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
    Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
    DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
    J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
    Lin L; Lu L; Cao W; Li T
    Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
    Zeng QL; Yu ZJ; Gou JJ; Li GM; Ma SH; Zhang GF; Xu JH; Lin WB; Cui GL; Zhang MM; Li C; Wang ZS; Zhang ZH; Liu ZS
    J Infect Dis; 2020 Jun; 222(1):38-43. PubMed ID: 32348485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 19. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
    Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
    Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of coronavirus disease 2019.
    Hung IFN
    Curr Opin HIV AIDS; 2020 Nov; 15(6):336-340. PubMed ID: 33002954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.